Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(129 products)
- CSF-1R(42 products)
- EGFR(593 products)
- Ephrin Receptor(25 products)
- FLT(90 products)
- Fibroblast Growth Factor Receptor (FGFR)(183 products)
- HER(3 products)
- Hck(3 products)
- IGF-1R(103 products)
- PDGFR(127 products)
- PYK2(7 products)
- Src(81 products)
- TAM Receptor(33 products)
- Tie-2(20 products)
- Trk receptor(57 products)
- Tyrosine Kinases(25 products)
- VEGFR(245 products)
- c-Fms(112 products)
- c-Kit(114 products)
- c-Met/HGFR(137 products)
- c-RET(62 products)
Show 13 more subcategories
Found 1170 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53Tyrosine Protein Kinase Substrate
CAS:Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.Formula:C66H109N23O23Molecular weight:1592.71HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34DDR1-IN-10
CAS:DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.Formula:C24H25F4N5O2Color and Shape:SolidMolecular weight:491.481DYR530
CAS:DYR530 is a ligand for the target protein (protein kinase DYRK1A) of PROTAC.Formula:C23H24FN7Color and Shape:SolidMolecular weight:417.48Enrupatinib
CAS:Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.Formula:C27H26N6O3Color and Shape:SolidMolecular weight:482.53c-Met-IN-26
CAS:c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formula:C24H19F2N9Color and Shape:SolidMolecular weight:471.46Fanregratinib
CAS:Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.Formula:C27H33ClN6O2Color and Shape:SolidMolecular weight:509.04JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54MerTK-IN-1
CAS:MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.Formula:C23H26N8O4Color and Shape:SolidMolecular weight:478.50Neptinib
CAS:Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formula:C22H23ClFN5O2Color and Shape:SolidMolecular weight:443.90EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColor and Shape:SolidMolecular weight:775.68Dyrk1A-IN-11
CAS:Dyrk1A-IN-11 (compound 166) is an effective inhibitor targeting dual-specificity tyrosine phosphorylation-regulated 1A (DYRK1A) with an EC50 of 0.0021 µM. Additionally, this compound inhibits the phosphorylation of Tau (Thr212) with an EC50 of 0.0361 µM.Formula:C23H23F5N8OColor and Shape:SolidMolecular weight:522.47HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidLSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854DDR1-IN-8
CAS:DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.Formula:C23H24F3N5O2Molecular weight:459.46EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61
